ARPO: AI 评分 43/100 — AI 分析 (4月 2026)

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for ocular diseases. Their lead product candidate, AKB-9778, targets diabetic retinopathy, with other pipeline programs addressing inflammatory bowel disease.

Key Facts: AI Score: 43/100 Sector: Healthcare

公司概况

概要：

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in ocular disease treatments, notably diabetic retinopathy, with its lead candidate AKB-9778. The company leverages Tie-2 pathway activation and HIF-1alpha stabilization in its drug development, positioning it within the competitive biotechnology landscape focused on unmet medical needs.

ARPO是做什么的？

Aerpio Pharmaceuticals Inc., headquartered in Blue Ash, Ohio, is a biopharmaceutical company dedicated to the research and development of treatments for ocular diseases. Founded with the mission of addressing unmet needs in ophthalmology, Aerpio has focused its efforts on developing innovative therapies for conditions such as diabetic retinopathy (DR) and diabetic macular edema (DME). The company's lead product candidate, AKB-9778, is a small molecule activator of the Tie-2 pathway, a crucial signaling pathway involved in maintaining vascular stability and reducing vascular leakage, which are key factors in the progression of DR and DME. In addition to AKB-9778, Aerpio has two other pipeline programs: AKB-4924 and ARP-1536. AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody targeting the same pathway as AKB-9778, inhibiting the interaction between vascular endothelial protein tyrosine phosphatase (VE-PTP) and Tie-2. Aerpio's approach involves targeting fundamental mechanisms underlying ocular diseases and exploring different modalities, including small molecules and antibodies, to address these mechanisms. As of April 14, 2017, Aerpio completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema and a Phase Ia clinical trial in healthy volunteers for AKB-4924. The company currently employs 12 full-time employees.

ARPO的投资论点是什么？

Aerpio Pharmaceuticals presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The primary value driver is the successful development and commercialization of AKB-9778 for diabetic retinopathy, a significant market with substantial unmet need. Positive Phase III trial results would serve as a major catalyst, potentially leading to FDA approval and subsequent revenue generation. However, the company's negative profit margin of -288.3% and reliance on a limited pipeline create substantial financial and clinical risks. Investors should closely monitor clinical trial outcomes, regulatory milestones, and the company's ability to secure additional funding to sustain operations.

ARPO在哪个行业运营？

Aerpio Pharmaceuticals operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy regulatory approval processes, and binary outcomes. The market for diabetic retinopathy treatments is substantial, driven by the increasing prevalence of diabetes globally. Aerpio's Tie-2 activation approach differentiates it from competitors focusing on anti-VEGF therapies. The company faces competition from established pharmaceutical companies and other biotechnology firms developing novel treatments for ocular diseases. Success hinges on demonstrating superior efficacy and safety compared to existing therapies.

Biotechnology

Healthcare

ARPO有哪些增长机遇？

Expansion of AKB-9778 into New Indications: Beyond diabetic retinopathy, AKB-9778's Tie-2 activation mechanism may have therapeutic potential in other vascular-related diseases, such as glaucoma or age-related macular degeneration (AMD). These indications represent significant market opportunities, potentially expanding the addressable patient population and extending the product's lifecycle. Clinical trials exploring these new indications would be necessary, requiring further investment and regulatory approvals. The market size for AMD alone is projected to reach billions of dollars, offering a substantial revenue opportunity.
Advancement of AKB-4924 for Inflammatory Bowel Disease (IBD): AKB-4924, a selective stabilizer of HIF-1alpha, targets IBD, a chronic inflammatory condition affecting the gastrointestinal tract. The IBD market is growing, driven by increasing prevalence and the development of new biologic therapies. Positive clinical trial results for AKB-4924 could position Aerpio as a player in this market. The global IBD market is estimated to be worth billions of dollars, presenting a significant growth opportunity for Aerpio.
Partnerships and Licensing Agreements: Aerpio could pursue partnerships or licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. These collaborations could provide upfront payments, milestone payments, and royalties on future sales, providing non-dilutive funding and access to established marketing and distribution networks. Successful partnerships would validate Aerpio's technology and enhance its credibility in the industry.
Development of ARP-1536: ARP-1536, a humanized monoclonal antibody targeting the same pathway as AKB-9778, offers a different modality for addressing ocular diseases. Advancing ARP-1536 through clinical development could provide a longer-acting therapeutic option compared to the small molecule AKB-9778. This could appeal to patients and physicians seeking less frequent dosing regimens. Further preclinical and clinical studies are needed to assess the safety and efficacy of ARP-1536.
Geographic Expansion: Initially focusing on the US market, Aerpio could expand its commercial operations to other regions, such as Europe and Asia, to reach a larger patient population. This would require establishing local regulatory approvals, marketing infrastructure, and distribution channels. The global market for diabetic retinopathy treatments is substantial, with significant growth potential in emerging markets.

Market capitalization of $0.05 billion reflects the company's early stage and speculative nature.
A P/E ratio of -7.39 indicates the company is currently unprofitable.
Profit margin of -288.3% highlights the significant expenses associated with drug development.
Beta of 1.65 suggests the stock is more volatile than the market average.
The company does not currently offer a dividend, consistent with its focus on reinvesting capital into research and development.

ARPO提供哪些产品和服务？

Researches and develops treatments for ocular diseases.
Focuses on therapies for diabetic retinopathy (DR) and diabetic macular edema (DME).
Develops small molecule activators of the Tie-2 pathway.
Develops selective stabilizers of hypoxia-inducible factor-1 alpha (HIF-1alpha).
Creates humanized monoclonal antibodies targeting vascular endothelial protein tyrosine phosphatase (VE-PTP).
Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.

ARPO如何赚钱？

Develops and patents novel pharmaceutical compounds.
Conducts preclinical and clinical trials to demonstrate safety and efficacy.
Seeks regulatory approval from agencies like the FDA.
Aims to commercialize approved drugs directly or through partnerships.
Generates revenue through product sales and licensing agreements.

Patients with diabetic retinopathy and diabetic macular edema.
Ophthalmologists and retina specialists who treat these patients.
Hospitals and clinics that provide eye care services.
Potential pharmaceutical partners for licensing or co-development agreements.

Proprietary drug candidates with patent protection.
Targeting the Tie-2 pathway, a novel mechanism of action in ocular disease.
Clinical trial data demonstrating efficacy and safety.
Expertise in drug development and regulatory affairs.
Potential for orphan drug designation for certain indications.

什么因素可能推动ARPO股价上涨？

Upcoming: Announcement of results from ongoing clinical trials of AKB-9778.
Upcoming: Potential FDA approval of AKB-9778 for diabetic retinopathy.
Ongoing: Progress in clinical development of AKB-4924 for inflammatory bowel disease.
Ongoing: Potential partnerships or licensing agreements with pharmaceutical companies.

ARPO的主要风险是什么？

Potential: Failure to secure additional funding to sustain operations.
Potential: Unfavorable results from clinical trials.
Potential: Regulatory delays or rejection of drug candidates.
Ongoing: Competition from other companies developing treatments for ocular diseases.
Ongoing: Dependence on key personnel.

ARPO的核心优势是什么？

Novel drug candidates targeting unmet needs in ocular disease.
Proprietary Tie-2 activation technology.
Completed Phase II trial for AKB-9778 in diabetic macular edema.
Pipeline programs addressing inflammatory bowel disease.

ARPO的劣势是什么？

Limited financial resources.
High dependence on the success of AKB-9778.
Negative profit margin.
Small number of employees.

ARPO有哪些机遇？

Expansion of AKB-9778 into new indications.
Partnerships with larger pharmaceutical companies.
Advancement of AKB-4924 and ARP-1536 through clinical development.
Geographic expansion into international markets.

ARPO面临哪些威胁？

Clinical trial failures.
Regulatory setbacks.
Competition from established pharmaceutical companies.
Difficulty securing additional funding.

ARPO的竞争对手是谁？

Achillion Pharmaceuticals, Inc. — Focuses on complement-related drug development. — (ACHL)
AlloVir, Inc. — Develops allogeneic T-cell therapies. — (ALVR)
bluebird bio, Inc. — Focuses on gene therapies for severe genetic diseases. — (BLUE)
Erytech Pharma S.A. — Encapsulates therapeutic enzymes inside red blood cells. — (ERYP)
Heat Biologics, Inc. — Develops immunotherapies for cancer. — (HTBX)

Key Metrics

MoonshotScore: 43/100

Company Profile

Headquarters: Blue Ash, US
Employees: 12
Founded: 2018

AI Insight

AI analysis pending for ARPO

常见问题

What does Aerpio Pharmaceuticals, Inc. do?

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research and development of treatments for ocular diseases, primarily diabetic retinopathy. Their lead product candidate, AKB-9778, is a small molecule activator of the Tie-2 pathway, aiming to reduce vascular leakage and improve vascular stability in the eye. The company also has pipeline programs targeting inflammatory bowel disease, demonstrating a broader interest in developing therapies for diseases with significant unmet medical needs. Aerpio seeks to develop and commercialize innovative treatments to improve patient outcomes in ophthalmology and related fields.

What do analysts say about ARPO stock?

Given the speculative nature of early-stage biotechnology companies, analyst opinions on ARPO stock are likely to be highly variable and sensitive to clinical trial results and regulatory milestones. Key valuation metrics would likely focus on the potential peak sales of AKB-9778 and other pipeline assets, discounted by the probability of success and time to market. Growth considerations would center on the successful completion of clinical trials, regulatory approval, and commercial launch. Due to the limited information available, a consensus view is difficult to ascertain without comprehensive analyst reports.

What are the main risks for ARPO?

The main risks for Aerpio Pharmaceuticals, Inc. include clinical trial failures, regulatory setbacks, and competition from established pharmaceutical companies. The company's reliance on a limited pipeline, particularly AKB-9778, makes it vulnerable to negative clinical trial outcomes. Securing additional funding to sustain operations is also a significant risk, as the company currently has a negative profit margin. Furthermore, the biotechnology industry is highly competitive, with numerous companies developing treatments for ocular diseases, potentially eroding Aerpio's market share.